Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Pfizer688 enrolled

Overview

This is a retrospective, multicenter, observational study in Japan by medical record review of advanced breast cancer (ABC) patients who have received palbociclib plus endocrine therapy (ET) as first line or second line setting. For the purposes of this study, analyses will be descriptive in nature. No formal hypothesis testing is planned.

Study Type

OBSERVATIONAL

Enrollment

688

Conditions

Breast Cancer

Interventions

PalbociclibDRUG

Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC

Endocrine therapyDRUG

Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of HR+/HER2- ABC * Age of 20 years or older at diagnosis of ABC * Patients that received palbociclib plus ET in the first line or second line * Patients who meet the criteria regarding the medical record below: * Patients with any medical records (regardless of palbociclib use) for more than 6 months from palbociclib initiation OR * Patients with any medical records for less than 6 months from palbociclib initiation AND who had specific events (death, disease progression, or treatment discontinuation of palbociclib due to adverse events) in the available records Exclusion Criteria: * Patients who received chemotherapy as first line treatment. * Patients who have previously participated or are participating in any interventional clinical trials that include investigational or marketed products. (Interventional clinical trials for early breast cancer and later line after palbociclib will be acceptable, Besides, patients participating in other investigator-initiated research or noninterventional studies can be included as long as their standard of care is not altered by the study.)

Locations (20)

Nagoya University Hospital

Nagoya, Aichi-ken, Japan

National Hospital Organization Shikoku Cancer Center

Matsuyama, Ehime, Japan

Outcomes

Primary Outcomes

Real-World Progression-Free Survival (rwPFS) of palbociclib plus ET as first line treatment for HR+/HER2- ABC